---
title: "Genmab Announces Major Shareholder Update with Orbis Investment"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/258559901.md"
description: "Genmab A/S announced that Orbis Investment Management Limited now controls 5.03% of its share capital and voting rights as of September 19, 2025. This major shareholder update may influence Genmab's strategic decisions. The latest analyst rating for GMAB stock is a Buy with a $43.00 price target, reflecting strong growth prospects despite recent challenges. Genmab, a biotechnology company based in Copenhagen, focuses on developing innovative antibody therapeutics and has a market cap of $17.68B."
datetime: "2025-09-23T15:17:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258559901.md)
  - [en](https://longbridge.com/en/news/258559901.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258559901.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/258559901.md) | [繁體中文](https://longbridge.com/zh-HK/news/258559901.md)


# Genmab Announces Major Shareholder Update with Orbis Investment

An update from Genmab ( (GMAB) ) is now available.

On September 23, 2025, Genmab A/S announced that Orbis Investment Management Limited now controls 5.03% of its share capital and voting rights, as of September 19, 2025. This major shareholder announcement highlights Orbis’s significant influence within Genmab, potentially impacting the company’s strategic decisions and market positioning.

The most recent analyst rating on (GMAB) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

**Spark’s Take on GMAB Stock**

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab’s overall stock score is driven by strong earnings call results and positive technical indicators, highlighting robust growth prospects and market momentum. The company’s solid financial performance, despite recent revenue and cash flow challenges, supports its stability. Valuation metrics suggest the stock is undervalued, offering potential upside. The absence of significant corporate events does not impact the score.

To see Spark’s full report on GMAB stock, click here.

**More about Genmab**

Genmab is an international biotechnology company focused on developing innovative and differentiated antibody therapeutics. Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific. The company specializes in next-generation antibody technology platforms, including bispecific T-cell engagers and antibody-drug conjugates, aiming to transform the lives of patients with cancer and other serious diseases by 2030.

**Average Trading Volume:** 1,322,061

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $17.68B

### 相关股票

- [Genmab A/S (GMAB.US)](https://longbridge.com/zh-CN/quote/GMAB.US.md)

## 相关资讯与研究

- [Genmab Discloses Orbis as New 5% Major Shareholder](https://longbridge.com/zh-CN/news/281419643.md)
- [Genmab A/S Teases 2026 Wave of Registrational Readouts for EPKINLY, Rina-S and Petosemtamab](https://longbridge.com/zh-CN/news/279516072.md)
- [Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)](https://longbridge.com/zh-CN/news/279006641.md)
- [Genmab Discloses CFO Insider Share Sale Under EU Market Abuse Rules](https://longbridge.com/zh-CN/news/276478570.md)
- [HC Wainwright bullish on Genmab A/S (GMAB) on robust sales for DARZALEX](https://longbridge.com/zh-CN/news/275885478.md)